Real-world dapagliflozin experience in patients with heart failure in Greece

Trial Identifier: D1699R00046
Sponsor: AstraZeneca
NCTID:: NCT05635331
Start Date: December 2022
Primary Completion Date: March 2025
Study Completion Date: March 2025
Condition: Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Greece Alexandroupoli, Greece, 68100
Greece Athens, Greece, 12462
Greece Athens, Greece, 14233
Greece Athens, Greece, 11528
Greece Athens, Greece, 17674
Greece Athens, Greece, 11526
Greece Athens, Greece, 11527
Greece Chania, Greece, 73300
Greece Heraclion, Greece, 71409
Greece Ioannina, Greece, 45500
Greece Ioannina, Greece, 45445
Greece Patra, Greece, 26504
Greece Thessaloniki, Greece, 57010
Greece Thessaloniki, Greece, 54636
Greece Thessaloniki, Greece, 54642
Greece Thessaloniki, Greece, 56429